Recently, LRG Board Member Dave Safford decided to sit down and think about all of the good fortune that has come into his life since being diagnosed with cancer. We liked his list so much we decided to share it so that everyone in the GIST community can see a story of positivity and hope.
The GIST Group of Switzerland awarded its science prize for the third time on November 22, 2012. It has been awarded ex aequo to Dr. Daniel Perez, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA, and Dr. Michael Montemurro, CHUV Lausanne/University Hospital Zurich.
If you have been mailed a fundraising packet and still have donor cards to send out, it is not too late. Consider passing one on to a neighbor co-worker, friend or family member.
The second annual GIST Day of Learning will be held on March 23, 2013. This year we are privileged once again that Dr. Jonathan Trent of Sylvester Cancer Center in Miami has agreed to host our gathering and we are honored to hear what he has to say.
The LRG is pleased to welcome Roger C. Campbell as our new Deputy Director. Roger, an attorney, brings to the LRG over 25 years of experience in the global financial services sector.
After two years of planning, toiling, and more planning, the LRG unveiled its redesigned website on January 1 at our same web address: liferaftgroup.org. Finding the balance between providing life-saving information and explaining GIST in a concise, understandable way, has always been a struggle for the Life Raft Group.
The LRG Research Team recently held a teleconference that focused primarily on a study the team will collaborate on and intends to publish.
Executive Director’s report focuses on better treatment options for GISTers For my Executive Director’s report, I usually highlight the many accomplishments of the Life Raft Group. Some of which include: Launching a GIST Day [...]
Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.
“It was such a frustrating time. It was awful,” Linda says, recalling how doctors had recommended she give Glaxo-SmithKline’s drug Votrient a shot but was unable to get Jessica’s insurance company to cover it despite appeals documented by GIST specialists.
